These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 17274112)

  • 21. Antigen specificity acquisition of adoptive CD4+ regulatory T cells via acquired peptide-MHC class I complexes.
    Hao S; Yuan J; Xu S; Munegowda MA; Deng Y; Gordon J; Xing Z; Xiang J
    J Immunol; 2008 Aug; 181(4):2428-37. PubMed ID: 18684933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
    Zhang Y; Wakita D; Chamoto K; Narita Y; Matsubara N; Kitamura H; Nishimura T
    Int Immunol; 2007 Feb; 19(2):151-61. PubMed ID: 17189593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
    Kalyanasundaram Bhanumathy K; Zhang B; Xie Y; Xu A; Tan X; Xiang J
    J Gene Med; 2015; 17(8-9):153-60. PubMed ID: 26212685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
    Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
    Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD4+ Th2 cells function alike effector Tr1 and Th1 cells through the deletion of a single cytokine IL-6 and IL-10 gene.
    Ankathatti Munegowda M; Xu S; Freywald A; Xiang J
    Mol Immunol; 2012 Jun; 51(2):143-9. PubMed ID: 22424785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity.
    Hao S; Bai O; Li F; Yuan J; Laferte S; Xiang J
    Immunology; 2007 Jan; 120(1):90-102. PubMed ID: 17073943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD4(+) T cells stimulate memory CD8(+) T cell expansion via acquired pMHC I complexes and costimulatory molecules, and IL-2 secretion.
    Shi M; Hao S; Chan T; Xiang J
    J Leukoc Biol; 2006 Dec; 80(6):1354-63. PubMed ID: 16980510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma.
    Yamanaka R; Honma J; Tsuchiya N; Yajima N; Kobayashi T; Tanaka R
    J Neurooncol; 2005 Apr; 72(2):107-13. PubMed ID: 15925989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo.
    Nishimura T; Iwakabe K; Sekimoto M; Ohmi Y; Yahata T; Nakui M; Sato T; Habu S; Tashiro H; Sato M; Ohta A
    J Exp Med; 1999 Sep; 190(5):617-27. PubMed ID: 10477547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
    Zhang X; Munegowda MA; Yuan J; Wei Y; Xiang J
    J Leukoc Biol; 2010 Aug; 88(2):393-403. PubMed ID: 20466823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.
    Nishimura F; Dusak JE; Eguchi J; Zhu X; Gambotto A; Storkus WJ; Okada H
    Cancer Res; 2006 Apr; 66(8):4478-87. PubMed ID: 16618775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dendritic cells activated by an anti-inflammatory agent induce CD4(+) T helper type 2 responses without impairing CD8(+) memory and effector cytotoxic T-lymphocyte responses.
    Wang Y; Da'Dara AA; Thomas PG; Harn DA
    Immunology; 2010 Mar; 129(3):406-17. PubMed ID: 19922421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes.
    Tsuji T; Yasukawa M; Matsuzaki J; Ohkuri T; Chamoto K; Wakita D; Azuma T; Niiya H; Miyoshi H; Kuzushima K; Oka Y; Sugiyama H; Ikeda H; Nishimura T
    Blood; 2005 Jul; 106(2):470-6. PubMed ID: 15790789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.
    Lutz-Nicoladoni C; Wallner S; Stoitzner P; Pircher M; Gruber T; Wolf AM; Gastl G; Penninger JM; Baier G; Wolf D
    Immunol Cell Biol; 2012 Jan; 90(1):130-4. PubMed ID: 21383769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T cytotoxic 1 and T cytotoxic 2 CD8 T cells both inhibit IgE responses.
    Thomas MJ; MacAry PA; Noble A; Askenase PW; Kemeny DM
    Int Arch Allergy Immunol; 2001; 124(1-3):187-9. PubMed ID: 11306964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD4(+) T cell-released exosomes inhibit CD8(+) cytotoxic T-lymphocyte responses and antitumor immunity.
    Zhang H; Xie Y; Li W; Chibbar R; Xiong S; Xiang J
    Cell Mol Immunol; 2011 Jan; 8(1):23-30. PubMed ID: 21200381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.